Analyst Reco. Novo Nordisk A/S

Equities

NOVO B

DK0062498333

Pharmaceuticals

Market Closed - Nasdaq Copenhagen Other stock markets 08:50:00 19/05/2026 pm IST			5-day change	1st Jan Change
287.50 ^DKK	+0.52%		-3.04%	-11.61%

19/05	Can Nvidia Do It Again?
19/05	Novo Nordisk highlights semaglutide for the treatment of silent liver disease	FW

Analyst Reco.

19/05	NOVO NORDISK : Barclays reiterates its Neutral rating	ZD
18/05	Novo Nordisk slides on signs of slowing sales momentum for Wegovy pill	FW
13/05	NOVO NORDISK : Jefferies reaffirms its Neutral rating	ZD
12/05	NOVO NORDISK : Bernstein keeps a Sell rating	ZD
11/05	Citi raises Novo Nordisk price target following strong Wegovy pill launch	FW
11/05	SB1: Market underestimates Novo Nordisk potential - raises price target	FW
11/05	SB1 Markets raises Novo Nordisk price target to DKK 350 (280), reiterates Buy	FW
11/05	Citigroup raises Novo Nordisk price target to DKK 290 (275), reiterates Neutral rating	FW
08/05	NOVO NORDISK : Deutsche Bank gives a Neutral rating	ZD
08/05	NOVO NORDISK : Gets a Neutral rating from JP Morgan	ZD
08/05	NOVO NORDISK : UBS sticks Neutral	ZD
08/05	NOVO NORDISK : Barclays sticks Neutral	ZD
08/05	DZ Bank trims Novo Nordisk price target to DKK 299 (307), reiterates Hold - BN	FW
08/05	Nykredit raises Novo Nordisk price target to DKK 350 (300), reiterates Buy - BN	FW
07/05	NOVO NORDISK : DZ Bank gives a Neutral rating	ZD
07/05	NOVO NORDISK : Deutsche Bank reiterates its Neutral rating	ZD
07/05	NOVO NORDISK : Gets a Neutral rating from Barclays	ZD
07/05	Danske Bank raises Novo Nordisk price target to DKK 355 (350), reiterates Buy - BN	FW
07/05	Novo Nordisk Price Target Rises as BMO Notes Wegovy Pill Uptake, FY26 Guidance	MT
06/05	Novo Nordisk: The tide has begun to turn
06/05	NOVO NORDISK : Bernstein remains a Sell rating	ZD
06/05	NOVO NORDISK : JP Morgan sticks Neutral	ZD
06/05	NOVO NORDISK : Goldman Sachs reiterates its Neutral rating	ZD
05/05	Novo Nordisk expected to post DKK 29 billion operating profit - Bloomberg	FW
29/04	NOVO NORDISK : JP Morgan reaffirms its Neutral rating	ZD